Precision Medicine in Hepatobiliary Diseases: A Clinical Review.
Keywords:
Hepatobiliary diseases, Precision medicine, Genetic basis, Non-Alcoholic Fatty Liver Disease (NAFLD), Intrahepatic cholangiocarcinoma.
Abstract
This review delves into the molecular intricacies of hepatobiliary diseases, emphasizing their genetic and molecular foundations. It explores the expanding scope of precision medicine, advocating for tailored approaches based on individual genomic profiles to enhance diagnostic and therapeutic strategies. The genetic and molecular basis of conditions such as hepatitis and cirrhosis are dissected, revealing specific mutations' roles in susceptibility and disease progression. The narrative underscores precision medicine's potential in steering hepatobiliary medicine toward personalized, effective healthcare models. Overall, advancements in genomic research promise targeted interventions for improved outcomes in managing complex hepatobiliary disorders.
References
1. Patel P, Dalal S. Hepatic Manifestations of Inflammatory Bowel Disease. Clin Liver Dis. 2021;17:292–6. Preprint at: https://doi.org/10.1002/cld.1046
2. Johnson KB, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2021;14:86–93. Preprint at: https://doi.org/10.1111/cts.12884
3. Strianese O, et al. Precision and personalized medicine: How genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes (Basel). 2020;11:1–24.
4. Wang RC, Wang Z. Precision Medicine: Disease Subtyping and Tailored Treatment. Cancers. 2023;15. Preprint at: https://doi.org/10.3390/cancers15153837
5. Wang JH. Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases. Biomedicines. 2023;11. Preprint at: https://doi.org/10.3390/biomedicines11041140
6. Daily JP, Maguire JH. Hepatobiliary Disease.
7. Strong A. Introduction: Genetic Hepatobiliary Disease. Clin Liver Dis. 2021;18:45–53. Preprint at: https://doi.org/10.1002/cld.1118
8. Kwok AJ, Mentzer A, Knight JC. Host genetics and infectious disease: new tools, insights and translational opportunities. Nat Rev Genet. 2021;22:137–53. Preprint at: https://doi.org/10.1038/s41576-020-00297-6
9. Jan R, Chaudhry GS. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull. 2019;9:205–18. Preprint at: https://doi.org/10.15171/apb.2019.024
10. Chen L, et al. Oncotarget 7204 Www.Impactjournals.Com/Oncotarget Inflammatory Responses and Inflammation-Associated Diseases in Organs. Oncotarget. 2018;9. www.impactjournals.com/oncotarget/
11. Sun H, et al. Factors Influencing Gallstone Formation: A Review of the Literature. Biomolecules. 2022;12. Preprint at: https://doi.org/10.3390/biom12040550
12. Uffelmann E, et al. Genome-wide association studies. Nat Rev Methods Primers. 2021;1. Preprint at: https://doi.org/10.1038/s43586-021-00056-9
13. Tam V, et al. Benefits and limitations of genome-wide association studies. Nat Rev Genet. 2019;20:467–84. Preprint at: https://doi.org/10.1038/s41576-019-0127-1
14. Jokinen JM, Luukkonen KP. Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease. Trends Pharmacol Sci. 2024;45(4):319–34. Preprint at: https://doi.org/10.1016/j.tips.2024.02.003
15. Zheng Y, Wang S, Wu J, Wang Y. Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy. J Transl Med. 2023;21. Preprint at: https://doi.org/10.1186/s12967-023-04367-1
16. Natesan V, Kim SJ. Lipid metabolism, disorders and therapeutic drugs – Review. Biomol Ther (Seoul). 2021;29:596–604. Preprint at: https://doi.org/10.4062/biomolther.2021.122
17. Bodaghi A, Fattahi N, Ramazani A. Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon. 2023;9. Preprint at: https://doi.org/10.1016/j.heliyon.2023.e13323
18. Kaushal A, et al. Current Update on Biomarkers for Detection of Cancer: Comprehensive Analysis. Vaccines. 2022;10. Preprint at: https://doi.org/10.3390/vaccines10122138
19. Wazir H, et al. Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions. Cureus. 2023. doi:10.7759/cureus.49920
20. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15. Preprint at: https://doi.org/10.1186/s13045-022-01351-y
21. Naithani N, et al. Precision medicine: Uses and challenges. Med J Armed Forces India. 2021;77:258–65. Preprint at: https://doi.org/10.1016/j.mjafi.2021.06.020
22. Denny JC, Collins FS. Precision medicine in 2030—seven ways to transform healthcare. Cell. 2021;184:1415–9. Preprint at: https://doi.org/10.1016/j.cell.2021.01.015
23. Johnson KB, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2021;14:86–93. Preprint at: https://doi.org/10.1111/cts.12884
24. Alqahtani A, et al. Hepatocellular carcinoma: Molecular mechanisms and targeted therapies. Medicina (Kaunas). 2019;55. Preprint at: https://doi.org/10.3390/medicina55090526
25. Lsloom MN, Lasloom SJM, ALsaloom MAH, ALsaloom HAH, Humayyim BMMM, Hadialyam MA, Mojabah AGM, HussienALmukalas AN, HussienAlmukalas GA, Salemhamadalyami N, Abdulaziz Nasser Mohammed Lsloom MNA, Lasloom MAJ. Critical analysis on integration of pharmacogenomics into nursing and pharmacy practices. 2022;17(2). Preprint at: https://doi.org/10.18011/2022.04(1)477.490
26. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018;109:952–63. Preprint at: https://doi.org/10.1016/j.fertnstert.2018.05.006
27. Choi HY, Chang JE. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. Int J Mol Sci. 2023;24. Preprint at: https://doi.org/10.3390/ijms241713618
28. Riedl JM, et al. Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view. Virchows Arch. 2023. Preprint at: https://doi.org/10.1007/s00428-023-03702-7
29. Mardinoglu A, Boren J, Smith U, Uhlen M, Nielsen J. Systems biology in hepatology: Approaches and applications. Nat Rev Gastroenterol Hepatol. 2018;15:365–77. Preprint at: https://doi.org/10.1038/s41575-018-0007-8
30. Zhou S, Sarabia FS, Estrine D, Ostrow D, Schmidt JR, Warren M, Raca G, Shillingford N, Wang L, Pawel B, Stein EJ, Biegel AJ, Terrada LD, Mascarenhas L, Ji J. Comparative Clinicopathologic and Genomic Analysis of Hepatocellular Neoplasm, Not Otherwise Specified, and Hepatoblastoma. Mod Pathol. 2023;37(2). Preprint at: https://doi.org/10.1016/j.modpat.2023.100385
31. Satam H, et al. Next-Generation Sequencing Technology: Current Trends and Advancements. Biology (Basel). 2023;12. Preprint at: https://doi.org/10.3390/biology12070997
32. Lema NK, Gemeda MT, Woldesemayat AA. Recent Advances in Metagenomic Approaches, Applications, and Challenge. Curr Microbiol. 2023;80. Preprint at: https://doi.org/10.1007/s00284-023-03451-5
33. Lei Y, et al. Applications of single-cell sequencing in cancer research: progress and perspectives. J Hematol Oncol. 2021;14. Preprint at: https://doi.org/10.1186/s13045-021-01105-2
34. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Med Oncol. 2022;39. Preprint at: https://doi.org/10.1007/s12032-022-01711-1
35. Akhoon N. Precision medicine: A new paradigm in therapeutics. Int J Prev Med. 2021;12. Preprint at: https://doi.org/10.4103/ijpvm.IJPVM_375_19
36. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12. Preprint at: https://doi.org/10.1186/s13073-019-0703-1
37. Kiyotani K, Toyoshima Y, Nakamura Y. Personalized immunotherapy in cancer precision medicine. Cancer Biol Med. 2021;18:955–65. Preprint at: https://doi.org/10.20892/j.issn.2095-3941.2021.0032
38. Aitcheson G, Mahipal A, John BV. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Expert Opin Investig Drugs. 2021;30:463–77. Preprint at: https://doi.org/10.1080/13543784.2021.1900821
39. Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res Commun. 2021;27. Preprint at: https://doi.org/10.1016/j.ctarc.2021.100356
40. Gmeiner WH. Recent advances in therapeutic strategies to improve colorectal cancer treatment. Cancers (Basel). 2024;16:1029. Preprint at: https://doi.org/10.3390/cancers16051029
41. Mamat Yusof MN, Ch’ng ES, Radhiah Abdul Rahman NB. BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14. Preprint at: https://doi.org/10.3390/cancers14225593
42. Boilève A, et al. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opin Investig Drugs. 2021;30:401–9. Preprint at: https://doi.org/10.1080/13543784.2021.1896703
43. Eso Y, Shimizu T, Takeda H, Takai A, Marusawa H. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol. 2020;55:15–26. Preprint at: https://doi.org/10.1007/s00535-019-01620-7
44. Botham J, Shilling V, Jones J. Patient and public understanding of the concept of ‘personalised medicine’ in relation to cancer treatment: a systematic review. Future Healthc J. 2021;8–8.
45. Tsumura T, Doi K, Marusawa H. Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. Cancers (Basel). 2022;14. Preprint at: https://doi.org/10.3390/cancers14153674
46. Newson AJ. The promise of public health ethics for precision medicine: the case of newborn preventive genomic sequencing. Hum Genet. 2022;141:1035–43. Preprint at: https://doi.org/10.1007/s00439-021-02269-0
2. Johnson KB, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2021;14:86–93. Preprint at: https://doi.org/10.1111/cts.12884
3. Strianese O, et al. Precision and personalized medicine: How genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes (Basel). 2020;11:1–24.
4. Wang RC, Wang Z. Precision Medicine: Disease Subtyping and Tailored Treatment. Cancers. 2023;15. Preprint at: https://doi.org/10.3390/cancers15153837
5. Wang JH. Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases. Biomedicines. 2023;11. Preprint at: https://doi.org/10.3390/biomedicines11041140
6. Daily JP, Maguire JH. Hepatobiliary Disease.
7. Strong A. Introduction: Genetic Hepatobiliary Disease. Clin Liver Dis. 2021;18:45–53. Preprint at: https://doi.org/10.1002/cld.1118
8. Kwok AJ, Mentzer A, Knight JC. Host genetics and infectious disease: new tools, insights and translational opportunities. Nat Rev Genet. 2021;22:137–53. Preprint at: https://doi.org/10.1038/s41576-020-00297-6
9. Jan R, Chaudhry GS. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull. 2019;9:205–18. Preprint at: https://doi.org/10.15171/apb.2019.024
10. Chen L, et al. Oncotarget 7204 Www.Impactjournals.Com/Oncotarget Inflammatory Responses and Inflammation-Associated Diseases in Organs. Oncotarget. 2018;9. www.impactjournals.com/oncotarget/
11. Sun H, et al. Factors Influencing Gallstone Formation: A Review of the Literature. Biomolecules. 2022;12. Preprint at: https://doi.org/10.3390/biom12040550
12. Uffelmann E, et al. Genome-wide association studies. Nat Rev Methods Primers. 2021;1. Preprint at: https://doi.org/10.1038/s43586-021-00056-9
13. Tam V, et al. Benefits and limitations of genome-wide association studies. Nat Rev Genet. 2019;20:467–84. Preprint at: https://doi.org/10.1038/s41576-019-0127-1
14. Jokinen JM, Luukkonen KP. Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease. Trends Pharmacol Sci. 2024;45(4):319–34. Preprint at: https://doi.org/10.1016/j.tips.2024.02.003
15. Zheng Y, Wang S, Wu J, Wang Y. Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy. J Transl Med. 2023;21. Preprint at: https://doi.org/10.1186/s12967-023-04367-1
16. Natesan V, Kim SJ. Lipid metabolism, disorders and therapeutic drugs – Review. Biomol Ther (Seoul). 2021;29:596–604. Preprint at: https://doi.org/10.4062/biomolther.2021.122
17. Bodaghi A, Fattahi N, Ramazani A. Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon. 2023;9. Preprint at: https://doi.org/10.1016/j.heliyon.2023.e13323
18. Kaushal A, et al. Current Update on Biomarkers for Detection of Cancer: Comprehensive Analysis. Vaccines. 2022;10. Preprint at: https://doi.org/10.3390/vaccines10122138
19. Wazir H, et al. Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions. Cureus. 2023. doi:10.7759/cureus.49920
20. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15. Preprint at: https://doi.org/10.1186/s13045-022-01351-y
21. Naithani N, et al. Precision medicine: Uses and challenges. Med J Armed Forces India. 2021;77:258–65. Preprint at: https://doi.org/10.1016/j.mjafi.2021.06.020
22. Denny JC, Collins FS. Precision medicine in 2030—seven ways to transform healthcare. Cell. 2021;184:1415–9. Preprint at: https://doi.org/10.1016/j.cell.2021.01.015
23. Johnson KB, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2021;14:86–93. Preprint at: https://doi.org/10.1111/cts.12884
24. Alqahtani A, et al. Hepatocellular carcinoma: Molecular mechanisms and targeted therapies. Medicina (Kaunas). 2019;55. Preprint at: https://doi.org/10.3390/medicina55090526
25. Lsloom MN, Lasloom SJM, ALsaloom MAH, ALsaloom HAH, Humayyim BMMM, Hadialyam MA, Mojabah AGM, HussienALmukalas AN, HussienAlmukalas GA, Salemhamadalyami N, Abdulaziz Nasser Mohammed Lsloom MNA, Lasloom MAJ. Critical analysis on integration of pharmacogenomics into nursing and pharmacy practices. 2022;17(2). Preprint at: https://doi.org/10.18011/2022.04(1)477.490
26. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018;109:952–63. Preprint at: https://doi.org/10.1016/j.fertnstert.2018.05.006
27. Choi HY, Chang JE. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. Int J Mol Sci. 2023;24. Preprint at: https://doi.org/10.3390/ijms241713618
28. Riedl JM, et al. Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view. Virchows Arch. 2023. Preprint at: https://doi.org/10.1007/s00428-023-03702-7
29. Mardinoglu A, Boren J, Smith U, Uhlen M, Nielsen J. Systems biology in hepatology: Approaches and applications. Nat Rev Gastroenterol Hepatol. 2018;15:365–77. Preprint at: https://doi.org/10.1038/s41575-018-0007-8
30. Zhou S, Sarabia FS, Estrine D, Ostrow D, Schmidt JR, Warren M, Raca G, Shillingford N, Wang L, Pawel B, Stein EJ, Biegel AJ, Terrada LD, Mascarenhas L, Ji J. Comparative Clinicopathologic and Genomic Analysis of Hepatocellular Neoplasm, Not Otherwise Specified, and Hepatoblastoma. Mod Pathol. 2023;37(2). Preprint at: https://doi.org/10.1016/j.modpat.2023.100385
31. Satam H, et al. Next-Generation Sequencing Technology: Current Trends and Advancements. Biology (Basel). 2023;12. Preprint at: https://doi.org/10.3390/biology12070997
32. Lema NK, Gemeda MT, Woldesemayat AA. Recent Advances in Metagenomic Approaches, Applications, and Challenge. Curr Microbiol. 2023;80. Preprint at: https://doi.org/10.1007/s00284-023-03451-5
33. Lei Y, et al. Applications of single-cell sequencing in cancer research: progress and perspectives. J Hematol Oncol. 2021;14. Preprint at: https://doi.org/10.1186/s13045-021-01105-2
34. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Med Oncol. 2022;39. Preprint at: https://doi.org/10.1007/s12032-022-01711-1
35. Akhoon N. Precision medicine: A new paradigm in therapeutics. Int J Prev Med. 2021;12. Preprint at: https://doi.org/10.4103/ijpvm.IJPVM_375_19
36. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12. Preprint at: https://doi.org/10.1186/s13073-019-0703-1
37. Kiyotani K, Toyoshima Y, Nakamura Y. Personalized immunotherapy in cancer precision medicine. Cancer Biol Med. 2021;18:955–65. Preprint at: https://doi.org/10.20892/j.issn.2095-3941.2021.0032
38. Aitcheson G, Mahipal A, John BV. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Expert Opin Investig Drugs. 2021;30:463–77. Preprint at: https://doi.org/10.1080/13543784.2021.1900821
39. Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res Commun. 2021;27. Preprint at: https://doi.org/10.1016/j.ctarc.2021.100356
40. Gmeiner WH. Recent advances in therapeutic strategies to improve colorectal cancer treatment. Cancers (Basel). 2024;16:1029. Preprint at: https://doi.org/10.3390/cancers16051029
41. Mamat Yusof MN, Ch’ng ES, Radhiah Abdul Rahman NB. BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14. Preprint at: https://doi.org/10.3390/cancers14225593
42. Boilève A, et al. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opin Investig Drugs. 2021;30:401–9. Preprint at: https://doi.org/10.1080/13543784.2021.1896703
43. Eso Y, Shimizu T, Takeda H, Takai A, Marusawa H. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol. 2020;55:15–26. Preprint at: https://doi.org/10.1007/s00535-019-01620-7
44. Botham J, Shilling V, Jones J. Patient and public understanding of the concept of ‘personalised medicine’ in relation to cancer treatment: a systematic review. Future Healthc J. 2021;8–8.
45. Tsumura T, Doi K, Marusawa H. Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. Cancers (Basel). 2022;14. Preprint at: https://doi.org/10.3390/cancers14153674
46. Newson AJ. The promise of public health ethics for precision medicine: the case of newborn preventive genomic sequencing. Hum Genet. 2022;141:1035–43. Preprint at: https://doi.org/10.1007/s00439-021-02269-0
Published
2024-07-10
How to Cite
Bansal, N., Kumar, A., Sharma, P., Anikhandi, S., Khare, S., & Arora, A. (2024). Precision Medicine in Hepatobiliary Diseases: A Clinical Review. Journal of Internal Medicine: Science & Art, 5, 21 - 32. https://doi.org/10.36013/jimsa.v5i.142
Issue
Section
Articles
Copyright (c) 2024 Journal of Internal Medicine: Science & Art
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
